Opus Genetics (IRD) Non-Current Deffered Revenue (2010 - 2018)
Opus Genetics (IRD) reported Non-Current Deffered Revenue of $19900.0 for Q4 2018, down 64.92% year-over-year from $56724.0 in Q4 2017, and down 33.33% on a QoQ basis from $29850.0 in Q3 2018.
Opus Genetics (IRD) has 9 years of Non-Current Deffered Revenue data on file, last reported at $19900.0 in Q4 2018.
- Quarterly Non-Current Deffered Revenue fell 64.92% year-over-year to $19900.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $19900.0 (down 64.92% YoY) and the FY2018 annual result came in at $19900.0, down 64.92% from the prior year.
- Non-Current Deffered Revenue slipped to $19900.0 in Q4 2018 per IRD's latest filing, from $29850.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $782280.0 in Q1 2014 and bottomed at $19900.0 in Q4 2018.
- The 5-year median for Non-Current Deffered Revenue is $134466.0 (2014), against an average of $293896.7.
- Peak annual rise in Non-Current Deffered Revenue reached 1317.58% in 2014, while the deepest fall reached 89.19% in 2014.
- Tracing IRD's Non-Current Deffered Revenue over 5 years: stood at $618750.0 in 2014, then slumped by 83.19% to $104020.0 in 2015, then declined by 23.86% to $79204.0 in 2016, then fell by 28.38% to $56724.0 in 2017, then slumped by 64.92% to $19900.0 in 2018.
- Per Business Quant, the three latest IRD Non-Current Deffered Revenue figures stand at $19900.0 (Q4 2018), $29850.0 (Q3 2018), and $39575.0 (Q2 2018).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 19,900.00 |
| Sep 30, 2018 | 29,850.00 |
| Jun 30, 2018 | 39,575.00 |
| Mar 31, 2018 | 48,150.00 |
| Dec 31, 2017 | 56,724.00 |
| Sep 30, 2017 | 61,557.00 |
| Jun 30, 2017 | 65,812.00 |
| Mar 31, 2017 | 431,250.00 |
| Dec 31, 2016 | 79,204.00 |
| Sep 30, 2016 | 468,750.00 |
| Jun 30, 2016 | 450,000.00 |
| Mar 31, 2016 | 506,250.00 |
| Dec 31, 2015 | 104,020.00 |
| Sep 30, 2015 | 543,750.00 |
| Jun 30, 2015 | 562,500.00 |
| Mar 31, 2015 | 581,250.00 |
| Sep 30, 2014 | 618,750.00 |
| Jun 30, 2014 | 134,466.00 |
| Mar 31, 2014 | 782,280.00 |
| Dec 31, 2013 | 833,630.00 |
| Sep 30, 2013 | 114,588.00 |
| Jun 30, 2013 | 1.24 Mn |
| Mar 31, 2013 | 55,184.00 |
| Dec 31, 2012 | 1.63 Mn |
| Sep 30, 2012 | 75,649.00 |
| Jun 30, 2012 | 85,883.00 |
| Mar 31, 2012 | 806,250.00 |
| Dec 31, 2011 | 104,388.00 |
| Sep 30, 2011 | 843,750.00 |
| Jun 30, 2011 | 122,893.00 |
| Dec 31, 2010 | 133,117.00 |